Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17714536 | 0.77 | ALDH1A1 (0.31) | SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL1140913 | 0.76 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL1140855 | 0.76 | — | — | |
| SCHEMBL13919892 | 0.76 | SIRT6 (0.30) | SIRT6 | |
| SCHEMBL506476 | 0.74 | L3MBTL1 (0.47) | SMN1; SMN2LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL307525 | 0.74 | — | — | |
| SCHEMBL11651593 | 0.74 | CYP2C19 (0.33) | — | |
| SCHEMBL10521581 | 0.71 | DRD2 (0.31) | — | |
| SCHEMBL1140929 | 0.71 | — | — | |
| Methane SCHEMBL27480548 | 0.71 | L3MBTL1 (0.32) | L3MBTL1ALDH1A1HPGDSIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114507184-B | Synthesis method and application of 1-methyl hexahydroazepin-4-one hydrochloride | 好医生药业集团有限公司 | 2024-02-13 | — | — | CN | claimed |
| CN-114507184-A | Synthesis method and application of 1-methylhexahydroazepin-4-one hydrochloride | 好医生药业集团有限公司 | 2022-05-17 | — | — | CN | claimed |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-04-24 | — | — | US | disclosed |
| CN-114507184-B | Synthesis method and application of 1-methyl hexahydroazepin-4-one hydrochloride | 好医生药业集团有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-114507184-B | Synthesis method and application of 1-methyl hexahydroazepin-4-one hydrochloride | 好医生药业集团有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-114507184-A | Synthesis method and application of 1-methylhexahydroazepin-4-one hydrochloride | 好医生药业集团有限公司 | 2022-05-17 | — | — | CN | disclosed |
| CN-114507184-A | Synthesis method and application of 1-methylhexahydroazepin-4-one hydrochloride | 好医生药业集团有限公司 | 2022-05-17 | — | — | CN | disclosed |
| US-20210238183-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2021-08-05 | — | — | US | disclosed |
| EP-3812387-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | Sumitomo Dainippon Pharma Oncology, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-10875864-B2 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| EP-0452101-B1 | Spiro bridged and unbridged heterocyclic compounds | ISRAEL INST BIOLOG RES (IL) | 1999-07-07 | — | — | EP | disclosed |
| EP-0888356-A1 | CONDENSED 2,3-BENZODIAZEPINE DERIVATIVES AND THEIR USE AS AMPA-RECEPTOR INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-01-07 | — | — | EP | disclosed |
| US-5852029-A | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1998-12-22 | — | — | US | disclosed |
| WO-1997028163-A1 | CONDENSED 2,3-BENZODIAZEPINE DERIVATIVES AND THEIR USE AS AMPA-RECEPTOR INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-08-07 | — | — | WO | disclosed |
| US-5534520-A | Spiro compounds containing five-membered rings | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1996-07-09 | — | — | US | disclosed |
| EP-0711292-A1 | AZA SPIRO COMPOUNDS ACTING ON THE CHOLINERGIC SYSTEM WITH MUSCARINIC AGONIST ACTIVITY | KOSMIN, Gerald, Emmanuel (GB) | 1996-05-15 | — | — | EP | disclosed |
| US-5407938-A | Treating central nervous system disorders; Alzheimer*s | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1995-04-18 | — | — | US | disclosed |
| WO-1995003303-A2 | AZA SPIRO COMPOUNDS ACTING ON THE CHOLINERGIC SYSTEM WITH MUSCARINIC AGONIST ACTIVITY | STATE OF ISRAEL, REPRESENTED BY THE PRIME MINISTER'S OFFICE, ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1995-02-02 | — | — | WO | disclosed |
| EP-0452101-A2 | Spiro bridged and unbridged heterocyclic compounds | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1991-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10875864-B2 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | PIM2, PIM1, PIM3 | SMN1; SMN2 3207/4885LMNA 1927/4885THRB 2910/4885 |
| US-20210238183-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | SMN1; SMN2 3075/4885LMNA 2351/4885THRB 703/4885 |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | SMN1; SMN2 3075/4885LMNA 2351/4885THRB 703/4885 |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | SMN1; SMN2 3075/4885LMNA 2351/4885THRB 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.